Loading...
In March 2026, the U.S. FDA approved insulin icodec (Awiqli), the first once-weekly basal insulin for adults with type 2 diabetes.
Frequent insulin injections can be burdensome for patients and caregivers. With its once-weekly dosing, icodec can substantially reduce this burden.
Approval was based on four large, industry-sponsored randomized trials comparing once-weekly icodec to a once-daily basal insulin (glargine or degludec) among patients with type 2 diabetes. Two trials were limited to insulin-naive patients, and two were limited to patients already using basal insulin. Together, the trials involved more than 2600 patients (mean age, ≈60; mean glycosylated hemoglobin, ≈8%).
In all four trials, measures of glycemic c…